International Pharmaceutical Aerosol Consortium on Regulation & Science
The International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS) is an international non-profit association comprised of companies that develop, manufacture, market, and support research and development of inhaled and nasal drugs and biologics (INDBs). IPAC-RS seeks to advance the science, and especially the regulatory science, of these products by collecting and analyzing data, conducting joint research and development projects, and engaging the wider community. Representing this industry sector for more than 25 years, IPAC-RS aims to build consensus and contribute to effective regulations and standards by sharing the results of its research through conferences, technical journals, webinars, and discussions with regulatory bodies.
IPAC-RS Roundtable Webinar Series 2025
In 2021, IPAC-RS launched a webinar series presented by SMEs in the pharmaceutical sciences, which enabled attendees the opportunity to learn about the latest research and regulatory trends. See the IPAC-RS Roundtables webpage for links to presentations and recordings for the webinars held in 2021 - 2024.
IPAC-RS continues its Roundtable series in 2025. The first webinar of 2025, Designing for a Sustainable Future: Strategies to Address the Device and Delivery System Lifecyle was held on April 1 2025. Visit the Roundtables webpage for information and to view the recording.
IPAC-RS Nasal Innovation Forum
Advancing Science, Shaping the Future of Nasal Drug Delivery
Thursday - Friday, September 18-19, 2025
West Trenton, New Jersey
This 1.5-day in-person event brought together industry leaders, regulatory experts, and scientific pioneers to explore the complexities of nasal drug development. This forum provided attendees a unique opportunity to engage in thought-provoking discussions, gain insights from expert speakers, and participate in collaborative roundtable sessions.
Visit the Forum webpage for more details. Presentations/Recordings will be available to the general public in 4-6 months.
IPAC-RS representatives contributed to the planning of and presented at the CRCG Workshop: Navigating the Transition to Low Global Warming Potential Propellants to be held on December 4-5, 2024.
Ann Purrington (Kindeva) presented An Introduction to the IPAC-RS Scenarios - Transition to LGWP Propellants in MDIs: Proposed Pathways to U.S. FDA Approval and Richard Lostritto, Ph.D. (Consultant/IPAC-RS Science Advisor) and Helen Strickland (GSK) presented on Statistical Considerations for the In Vitro Comparisons of Critical Product Performance Attributes for an Approved MDI Product Transitioning to LGWP Propellant.
Podium presentations and recordings are now available at the weblink above.
News and Events
December 2025
The IPAC-RS GRRO Alternate Propellants Working Group prepared a white paper Opportunities to Facilitate the Transition of pMDIs to Third-Generation Propellants available for download.
March 2025
We encourage you to take a look at the IPAC-RS 2024 Year in Review!
The report highlights the impressive work IPAC-RS accomplished in 2024.
January 2025
IPAC-RS is proud to announce the release of its 2025-2027 Strategic Plan. Please visit the Plan webpage for more details.
